Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
- Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura® (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707), an oral JAK1 inhibitor
Incyteto host an in-person analyst and investor event on Saturday, March 18, 2023, from 5:30-7:00 p.m. CTto discuss key vitiligo data presentations
New data from the Phase 3 TRuE-V clinical trial program evaluating the durability and long-term response (up to 104 weeks) of Opzelura® (ruxolitinib) cream in patients (age ≥12 years) with vitiligo will be presented in two late-breaking oral presentations, building on the previously announced positive 24- and 52-week results from the TRuE-V1 and TRuE-V2 studies. Additionally, safety and efficacy data from a Phase 2b study of povorcitinib, an investigational oral small-molecule JAK1 inhibitor, in patients with vitiligo will be presented as an oral presentation during a late-breaking abstract session.
“The research being featured at this year’s AAD Annual Meeting highlights the potential of
Key abstracts include:
Late-Breaking Oral Presentations
Relapse and Maintenance of Clinical Response in the Randomized Withdrawal Arm of the TRuE-V Long-Term Extension Phase 3 Study of Ruxolitinib Cream in Vitiligo (Session: S025 –
Facial and Total Vitiligo Area Scoring Index Response Shift During 104 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Results from the Open-Label Arm of the TRuE-V Long-Term Extension Phase 3 Study (Session: S025 –
Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 –
Posters with Oral Presentation
Ruxolitinib Cream Monotherapy Use Demonstrates Maintenance of Disease and Symptom Control with Use as Needed in Adults and Adolescents with Atopic Dermatitis: Pooled Analysis from the Long-Term Safety Periods of Two Phase 3 Studies (Abstract #44103. Session: Atopic Dermatitis.
Vitiligo Noticeability Scale Score Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43959. Session: Pigmentary Disorders & Vitiligo.
Facial Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43912. Session: Pigmentary Disorders & Vitiligo.
For e-Poster exhibits, abstract content will be available in the online viewing portal and on-site at the viewing stations. They will also be published online via the
Graft-Versus-Host Disease (GVHD)
Oral Ruxolitinib Treatment for Patients with Dermatologic Manifestations of Acute or Chronic Graft-Versus-Host Disease: A Post Hoc Analysis of the Phase 3
Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43938. Session: Pigmentary Disorders & Vitiligo.)
Treatment-Emergent Adverse Events of Interest for Janus Kinase Inhibitors: Pooled Analysis of the 52-Week TRuE-V Phase 3 Studies of Ruxolitinib Cream Treatment for Vitiligo (Abstract #43978. Session: Pigmentary Disorders & Vitiligo.)
Understanding the Patient Perspective in Living with and Treating Vitiligo (Abstract #43040. Session: Pigmentary Disorders & Vitiligo.)
More information regarding the 2023 AAD Annual Meeting can be found at https://www.aad.org/member/meetings-education/am23.
In-Person Event and Webcast
Conference call details will be provided on our website.
About Opzelura® (ruxolitinib) Cream
Opzelura® (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the
Opzelura is a registered trademark of
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis. A Phase 3 study in HS is also ongoing.
About Jakafi® (ruxolitinib)
Jakafi® (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the
Jakafi is marketed by
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.
Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, lichen planus, lichen sclerosus and prurigo nodularis.
To learn more, visit the Dermatology section of Incyte.com.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding Incyte’s dermatology portfolio, the presentation of clinical data for that portfolio, whether or when any products, development compounds, or combinations in that portfolio will be approved or commercially available for use in humans anywhere in the world (beyond those products already approved for certain indications in specific regions), whether and when approved products from Incyte’s dermatology portfolio will provide successful treatment options for dermatology patients, along with Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on
1 Jakafi (ruxolitinib) tablets: Prescribing Information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005672/en/
+1 302 498 6171
+1 302 274 4773